Wegovy and Zepbound belong to the same class of medications, known as GLP-1s, but they work in slightly different ways. In a recent head-to-head study, Zepbound was shown to be more effective than ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

If you want to continue GLP-1 therapy, you’ll likely need to switch to a brand-name GLP-1. Examples of these include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound).

In interviews, patients said that they had specifically sought out Zepbound and didn’t want to switch. “I chose Zepbound with my doctor,” said Carl Houde, 49, of Saugus, Mass.

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. What is gestational diabetes?

Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Nearly twice as many patients on Zepbound lost at least 25% of their body weight as those on Wegovy. Additionally, 81.6% of Zepbound patients lost 10% or more, versus 60.5% of those on Wegovy.